Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161744 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD
A Phase 1 study, sponsored by Arkansas Heart Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02161744: Clinical Trial Phase 1 study, sponsored by Arkansas Heart Hospital.
NCT02161744 is a Phase 1 study that was terminated before completion, run by Arkansas Heart Hospital. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02161744, a Phase 1 study, was terminated before completion, sponsored by Arkansas Heart Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is: 1.- to assess the safety and tolerability of autologous adipose derived stem cells (aADSC) administered intravenously in patients with chronic obstructive pulmonary disease, and 2.- to assess if this therapy results in less decrease of lung function parameters (FEV1, FEV1/FVC and 6 min walking distance) compared with a control baseline of 6 weeks. Patients will be followed up for 12 months after the therapy.
Primary Outcome
Safety/tolerability of Adipose Derived Stem Cell (ADSC) in patients with Chronic Obstructive Pulmonary Disease (COPD) during the twelve-month study period as determined by the incidence and severity of of adverse events.
Interventions
- BIOLOGICAL ADSCs administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-10-10 |
| Est. Completion | 2018-10-29 |
| Phase | Phase 1 |
Why NCT02161744 stopped before completion
NCT02161744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which ADSCs administration is the first listed.
NCT02161744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02161744 about?
NCT02161744 is a clinical study titled "Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD". The purpose of this study is: 1.- to assess the safety and tolerability of autologous adipose derived stem cells (aADSC) administered intravenously in patients with chronic obstructive pulmonary disease, and 2.- to assess if this therapy results in less decrease of lung function parameters (FEV1, FE...
What is the current status of trial NCT02161744?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-10-10. Estimated completion is 2018-10-29.
What interventions are being tested in trial NCT02161744?
The interventions under investigation include: ADSCs administration (BIOLOGICAL).
Who is sponsoring clinical trial NCT02161744?
This trial is sponsored by Arkansas Heart Hospital, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02161744's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI